Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy-Reference-Cited by-同舟云学术

Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy

Published:2018-08-14 Issue:10 Volume:48 Page:950-952
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Hashimoto Hironobu¹,Abe Masakazu²,Yanai Takako¹,Yamaguchi Takuhiro³,Zenda Sadamoto⁴⁵⁶,Uchitomi Yosuke⁵⁶,Fukuda Haruhiko⁷,Mori Mikio⁷,Iwasa Satoru⁸,Yamamoto Noboru⁹,Ohe Yuichiro¹⁰

Affiliation:

1. Department of Pharmacy, National Cancer Center Hospital

2. Department of Gynecologic Oncology, Shizuoka Cancer Center

3. Department of Biostatistics, Tohoku University Graduate School of Medicine

4. Department of Radiation Oncology, National Cancer Center Hospital East

5. Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital

6. Japan Supportive, Palliative and Psychosocial Oncology Group: J-SUPPORT

7. Data Management Section, National Cancer Center Hospital

8. Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital

9. Department of Experimental Therapeutics, National Cancer Center Hospital

10. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/48/10/950/26001154/hyy114.pdf

Reference11 articles.

1. Proposal for Classifying the Acute Emetogenicity of Cancer Chemotherapy;Hesketh;J Clin Oncol,1997

2. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy:TRIPLE study;Suzuki;Ann Oncol,2016

3. Radioreceptor binding profile of the atypical antipsychotic olanzapine;Bymaster;Neuropsychopharmacology,1996

4. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding;Schotte;Psychopharmacology (Berl),1996

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents;Supportive Care in Cancer;2023-12-21

2. Incorporation of Palliative Care in Gynecologic Oncology;Current Oncology Reports;2023-10-04

3. Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug;Current Oncology;2022-10-31

4. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting;The Breast;2020-12

5. Plant Extracts as Possible Agents for Sequela of Cancer Therapies and Cachexia;Antioxidants;2020-09-07